Bioventus Inc. (BVS) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001665988 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 27, 2026 | Aug 5, 2026 | $153.2M | $33.4M | $0.47 | Filing |
| Mar 28, 2026 | May 6, 2026 | $132.1M | $3.1M | $0.04 | Filing |
| Dec 31, 2025 | Mar 5, 2026 | $157.9M | $14.8M | $0.21 | Filing |
| Sep 27, 2025 | Nov 4, 2025 | $138.7M | $3.2M | $0.05 | Filing |
| Jun 28, 2025 | Aug 6, 2025 | $147.7M | $7.5M | $0.11 | Filing |
| Mar 29, 2025 | May 6, 2025 | $123.9M | $-2.6M | $-0.04 | Filing |
| Dec 31, 2024 | Mar 11, 2025 | $153.6M | $-388,000 | $0.00 | Filing |
| Sep 28, 2024 | Nov 5, 2024 | $139.0M | $-5.2M | $-0.08 | Filing |
What would Bioventus Inc. have to report for its valuation to change?
At $13.30, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 8.1% a year, to $1.14. On that path the next quarter needs diluted EPS near $0.05, against $0.05 in the quarter ended Sep 27, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 8.1% | 8.1% |
| EPS needed in final year | $1.14 | $1.14 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. BVS goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.